HC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $55 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Bicycle Therapeutics (NASDAQ:BCYC) and maintained a price target of $55.
August 07, 2024 | 8:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Bicycle Therapeutics and maintained a price target of $55.
The reiteration of a Buy rating and a maintained price target of $55 by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100